Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Total Liabilities: 2019-2025

Historic Total Liabilities for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $373.1 million.

  • Harmony Biosciences Holdings' Total Liabilities rose 12.60% to $373.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $373.1 million, marking a year-over-year increase of 12.60%. This contributed to the annual value of $340.0 million for FY2024, which is 1.28% down from last year.
  • Harmony Biosciences Holdings' Total Liabilities amounted to $373.1 million in Q3 2025, which was up 11.40% from $334.9 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Total Liabilities peaked at $373.1 million during Q3 2025, and registered a low of $229.4 million during Q1 2021.
  • Its 3-year average for Total Liabilities is $323.1 million, with a median of $331.6 million in 2024.
  • In the last 5 years, Harmony Biosciences Holdings' Total Liabilities decreased by 25.15% in 2021 and then rose by 27.09% in 2023.
  • Quarterly analysis of 5 years shows Harmony Biosciences Holdings' Total Liabilities stood at $246.9 million in 2021, then grew by 9.76% to $271.0 million in 2022, then grew by 27.09% to $344.5 million in 2023, then fell by 1.28% to $340.0 million in 2024, then increased by 12.60% to $373.1 million in 2025.
  • Its last three reported values are $373.1 million in Q3 2025, $334.9 million for Q2 2025, and $335.0 million during Q1 2025.